United Kingdom


Migraine remains undiagnosed and undertreated in at least 50% of patients, and less than 50% of migraine patients consult a physician.1

Migraine is the third most common condition in the world, impacting an estimated 1 in 7 people worldwide.2 The financial burden of migraine is huge – it costs the UK economy an estimated £3.42 billion per year.3


AJOVY® is indicated for the prophylaxis of migraine in adults who have at least four migraine days per month, and is the only licensed anti-CGRP therapy to offer quarterly and monthly dosing options.4


For more information please click here

Learn more
  • Teva in Migraine & Headache - interview with Joshua M. Cohen MD, MPH, FAHS - Senior Director, Theraputic Lead for Migraine & Headache, Teva Global Medical Affairs



[1] Pavone E et al. Patterns of triptans use: a study based on the records of a community pharmaceutical department. Cephalalgia. 2007;27(9):1000-4

[2] https://www.migrainetrust.org/about-migraine/migraine-what-is-it/facts-figures/ [Accessed 23/07/2019]

[3] Key Facts & Figures About Migraine, The Migraine Trust

[4] AJOVY® SmPC. Teva UK Limited

Teva Ref: HC610